The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis.

The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. - The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016826

Enrollment

Registered

2015-03-31

Start date

2015-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis (IPF)

Interventions

Pirfenidone Observation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed as IPF, as defined by the 2011 ATS/ERS/JRS/ALAT statement.

Exclusion criteria

Exclusion criteria: 1. The patients who disagree with involving in this study. 2. The patients had taken oral steroid medication and immunosuppressive therapy. 3. The patients who diagnosed as respiratory disorders other than IPF, malignancy, overt cardiac failure, and hepatic and renal disease.

Design outcomes

Primary

Measure	Time frame
Oxidative stress markers	—

Secondary

Measure	Time frame
Pulmonary function test, 6-minute walking test, St. George's Respiratory Questionnaire, Inflammatory cytokine, Incidence rate of acute exacerbation, Exacerbation-free survival time	—

Countries

Japan

Contacts

Public ContactSHUJI OH-ISHI

National Hospital Organization Ibarakihigashi National Hospital Department of Respiratory Medicine

ooishi.shuji.dg@mail.hosp.go.jp+81-29-282-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026